Cyclosporine A promotes renal fibrosis through activating endoplasmic reticulum stress by targeting miR-212-5p/ATF6 axis Authors: Juan Wang, Zheng Li, Bei Qing, Zhenkun Xia, Yunchang Yuan, Lei Zhang, Zhiwen Liu Published: 2026 ABSTRACT IntroductionCyclosporine A (CsA) is a widely used immunosuppressive drug, but its long-term use is associated with renal fibrosis. Despite its clinical importance, the molecular mechanisms underlying CsA-induced renal fibrosis remain poorly understood.MethodsWe used C57BL/6 mice (n = 6 per group) treated with CsA (30 mg/kg/day, gavage) and Boston University mouse proximal tubular (BUMPT) cells (n = 6 per group) exposed to CsA (8 µM). Assessments included Masson’s trichrome staining, Western blot, quantitative real-time PCR, immunohistochemistry, and in situ hybridization. Mechanistic studies employed miR-212-5p mimics and inhibitors, activating transcription factor 6 (ATF6) overexpression, and the endoplasmic reticulum (ER) stress inhibitor 4-phenylbutyric acid (4-PBA). Data are presented as mean ± standard deviation; statistical significance was defined as p < 0.05.ResultsCsA induced significant renal fibrosis in vivo and in vitro, evidenced by increased collagen deposition and elevated expression of alpha-smooth muscle actin (α-SMA), fibronectin, collagen type I and IV, and key profibrotic factors (p < 0.05). RNA analysis revealed that miR-212-5p was markedly upregulated in CsA-treated kidneys, predominantly in renal tubules. Concurrently, ATF6, a protective component of the unfolded protein response (UPR), was significantly downregulated. Bioinformatics prediction and luciferase reporter assays confirmed that miR-212-5p directly targets the 3′ untranslated region of Atf6 mRNA. Functionally, miR-212-5p mimic exacerbated CsA-induced ATF6 suppression and fibrosis, whereas anti–miR-212-5p restored ATF6 expression, attenuated ER stress, and significantly reduced fibrotic markers. Similarly, ATF6 overexpression or ER stress inhibition with 4-PBA ameliorated CsA-induced fibrosis.ConclusionsOur findings position miR-212-5p as a previously unrecognized molecular target of CsA and establish the miR-212-5p/ATF6 axis as a central driver of CsA-induced nephrotoxicity. The findings provide new insights into the molecular mechanisms of CsA nephrotoxicity and identify a potential therapeutic target for preventing CsA-induced renal fibrosis.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12967-026-08252-5. Introduction Cyclosporine A (CsA) is a well-established immunosuppressive agent widely used in organ transplantation and autoimmune diseases. Nevertheless, long-term CsA use is frequently associated with significant nephrotoxicity, manifested as chronic CsA-induced nephropathy with prominent renal fibrosis, which largely limits the clinical applications of CsA [1, 2]. In the initial phase of CsA-induced nephrotoxicity, the pathological alterations in the kidney are reversible. These changes can be mitigated by decreasing the dosage of CsA. However, when CsA is used over an extended period, it inflicts irreversible harm on renal function, ultimately resulting in renal failure [1, 3, 4]. However, despite CsA has significant nephrotoxicity, there are currently no effective alternative drugs. Therefore, CsA and other calcineurin inhibitors (CNIs) remain the mainstay of immunosuppressive therapy in transplantation. Consequently, there is an urgent need to develop therapeutic approaches to control the nephrotoxicity of CsA. The mechanisms by which CsA drives renal fibrosis are intricate and multifaceted. Currently, multiple research papers have reported that several crucial biological processes, including oxidative stress, which leads to cellular damage by generating excessive reactive oxygen species (ROS), inflammatory response characterized by the release of cytokines, and epithelial-mesenchymal transition (EMT), are all involved in the renal fibrosis caused by CsA [5–9]. However, despite these progresses made so far, the mechanisms underlying renal fibrosis induced by CsA still remain unclear. The endoplasmic reticulum (ER) is an essential organelle involved in protein synthesis, folding, and post-translational modification. Under normal physiological conditions, the ER maintains a delicate balance between protein folding and degradation. However, various pathological stimuli, such as oxidative stress, nutrient deprivation, and calcium dysregulation, can disrupt this balance, leading to the accumulation of unfolded or misfolded proteins in the ER lumen, a state known as ER stress [10]. To counteract ER stress, cells activate the unfolded protein response (UPR), a highly conserved signaling pathway. The UPR consists of three main branches: the inositol-requiring enzyme 1 (IRE1), PKR-like ER kinase (PERK), and activating transcription factor 6 (ATF6) pathways [10, 11]. Emerging evidence implicates ER stress as a key contributor to renal fibrogenesis. In response to renal injury, ER stress is activated in multiple renal cell types, including tubular epithelial cells, fibroblasts, and endothelial cells. Prolonged or unresolved ER stress can activate pro-fibrotic signaling pathways [12, 13]. The UPR can activate the transforming growth factor-β (TGF-β)/Smad pathway, a key regulator of extracellular matrix (ECM) production. TGF-β stimulates the synthesis and secretion of ECM proteins by fibroblasts and promotes EMT in tubular epithelial cells [12]. Moreover, ER stress can induce apoptosis and inflammation in renal cells, exacerbating the fibrotic process [14]. In our Lab, a study conducted by Shu et al. have indicated that ER stress is activated in post-ischemic kidneys to promote chronic kidney disease [15]. And in another study, they also unveil a reciprocal regulation between ER stress and autophagy in chronic kidney injury and fibrosis [16]. Importantly, there have been also some recent reports indicating that CsA can promote ER stress. For example, a study conducted by Mutig et al. indicated that CsA could induce proapoptotic ER stress in renal tubular cells [17]. In addition, Wu et al. also found that the levels of ER stress proteins were elevated in CsA-induced renal injury [18]. Based on these findings, we speculate that CsA may promote renal fibrosis by activating ER stress. Importantly, among the UPR pathways, ATF6 plays a uniquely protective role by transcriptionally upregulating ER chaperones, folding enzymes, and components of the ER-associated degradation machinery. Loss of ATF6 function exacerbates tissue injury in various disease models, including kidney fibrosis [19–22]. Yet, the mechanisms responsible for ATF6 suppression in CsA nephropathy have not been elucidated. Here, we uncover a novel regulatory axis in CsA-induced renal fibrosis: CsA upregulates microRNA-212-5p, which directly targets and silences Atf6 mRNA, thereby disabling a critical adaptive arm of the UPR. This miR-212-5p-mediated repression of ATF6 leads to unresolved ER stress, hyperactivation of pro-fibrotic pathways, and excessive extracellular matrix deposition. Our findings position miR-212-5p as a previously unrecognized molecular target of CsA and establish the miR-212-5p/ATF6 axis as a central driver of CsA-induced nephrotoxicity. This discovery not only advances our mechanistic understanding of calcineurin inhibitor-associated fibrosis but also highlights miR-212-5p inhibition or ATF6 activation as promising strategies to mitigate CsA-induced kidney injury without compromising its immunosuppressive efficacy. Materials and methods Antibodies and reagents Antibodies utilized in this research were procured from several suppliers. Anti-alpha smooth muscle Actin (ab5694), anti-fibronectin (ab2413), anti-collagen type I (ab6308) and anti-collagen type IV (ab308360) were from abcam; Anti-BiP (3177 S), anti-CHOP (2895) and anti-GAPDH (5174) were obtained from Cell Signaling Technology; Anti-ATF6 (24169-1-AP) was obtained from Proteintech. FITC-or rhodamine-conjugated goat anti-rabbit IgG were sourced from Abcam. 4-PBA (S4125) was from Selleck. Trizol was from CWBIO. PrimeScriptTM RT reagent Kit with gDNA Eraser and TB GreenTM Premix Ex Taq II was from TaKaRa. Digoxigenin-labeled mmu–miR-212-5p LNA probes and the In Situ Hybridization Kit from Servicebio; and miR-211-5p mimic, anti–miR-211-5p LNA, ATF6 plasmid and NC oligonucleotide from Ribo Biotechnology. Animals Male C57BL/6 mice, 7 weeks old, were sourced from Slaccas Animal Laboratory (Changsha, China). Prior to experiments, the mice were acclimated to a 12-hour light/dark cycle at 24 °C with 50% humidity and had unrestricted access to food and water for at least one week. The Institutional Animal Care and Use Committee approved the experimental protocols. Mice were then administered either olive oil (5 ml/kg) or olive oil-suspended CsA (30 mg/kg) by gavage once a day for 2 weeks [23]. For 4-PBA treatment, 4-PBA was dissolved in saline and then administrated once daily by intraperitoneal injection till the day before sacrificing with a dosage of 20 mg/kg 15. In certain experiments, mice were administered anti-miR-211-5p LNA, miR-211-5p mimic, or NC oligonucleotide LNA via tail vein injection. In the indicated time, the mice were anaesthetized with 2–3% isoflurane. Plasma and renal tissues were collected for further analysis. In our study, a total of 6 mice per group were used in the main in vivo experiments unless otherwise specified. RNA sequencing and bioinformatics analysis Total RNA was isolated from renal cortex tissues of CsA-treated and vehicle control mice (n = 3 per group) using TRIzol reagent. RNA quality and concentration were assessed with a NanoDrop spectrophotometer and Agilent Bioanalyzer. Libraries were constructed using the Illumina TruSeq Stranded mRNA Kit and sequenced on an Illumina NovaSeq 6000 platform to generate 150-bp paired-end reads. Differentially expressed genes (DEGs) were defined as those with |log₂(fold change)| > 1 and p < 0.05. Gene Ontology (GO) and KEGG pathway enrichment analyses were performed using Metascape. Cell culture The Boston University mouse proximal tubular cell line (BUMPT) was originally provided by Wilfred Lieberthal (Boston University School of Medicine, Boston, Massachusetts, USA). The cells were cultured in DMEM medium containing 10% FBS. For CsA treatment, BUMPT cells at an 80%–90% confluence was maintained in DMEM medium containing 10% FBS plus 8 µM CsA and cultured for indicated time. For 4-PBA treatment, 1 mM of 4-PBA was added concurrently with CsA. In some experiments, 200 nM miR-212-5p mimic, 200 nM anti-miR-212-5p, 50 nm ATF6 plasmid, or NC oligonucleotides were transfected into BUMPT cells with Lipofectamine 2000 following the manufacturer’s instructions [5, 9]. Western blotting Under reducing conditions, proteins were subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After separation, the proteins were transferred onto polyvinylidene fluoride (PVDF) membranes. To prevent non -specific binding of antibodies, the membranes were blocked with a 5% skimmed milk solution at room temperature for 1 h. Subsequently, the membranes were incubated overnight at 4 °C with primary antibodies that specifically recognize the target proteins. Following thorough washing to remove unbound primary antibodies, the membranes were incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibodies at room temperature for 1 h. Finally, protein bands were visualized using an enhanced chemiluminescence (ECL) kit (Thermo Fisher Scientific, 32106), which generates a detectable signal upon reaction with the HRP enzyme. qPCR Total RNA was isolated from kidney tissues or cultured BUMPT cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Different procedures were employed for miRNA and mRNA analyses. For miRNA quantification, reverse transcription was carried out with the TaqMan advanced miRNA cDNA synthesis kit (A28007; Applied Biosystems). Subsequently, qPCR was executed utilizing the TaqMan miRNA assay kit (4440887; Applied Biosystems). In addition, the miRNA expression levels were normalized to the small nuclear RNA U6, which served as the endogenous reference control. In the case of mRNA analysis, the M-MLV Reverse Transcriptase cDNA Synthesis Kit (TaKaRa) was used to generate complementary DNA (cDNA) from the isolated RNA. qPCR reactions were performed in triplicate using the TB Green™ Premix Ex Taq II reagent (TaKaRa). Glyceraldehyde- 3-phosphate dehydrogenase (GAPDH) served as the internal control for mRNA expression normalization. The experimental data were analyzed using the LightCycler 96 SW 1.1 software. The relative expression levels of miRNAs and mRNAs were calculated using the 2 - ΔΔCt method, which allows for a reliable comparison of gene expression across different samples. In situ hybridization (ISH) To detect microRNA expression in kidney tissues, in situ hybridization was carried out according to the methods detailed in our previous research [24, 25]. The process started with the paraffin-embedded kidney tissue sections. First, these sections were deparaffinized and rehydrated. After that, they were exposed to 20 µg/mL proteinase K to make the cell membranes permeable. Subsequently, the tissue sections were placed in a pre-hybridization solution and incubated at 78 °C for an hour. Then, a digoxigenin-labeled mmu–miR-212-5p LNA probe was used for an overnight hybridization at 37 °C. To prevent non-specific binding, the sections were incubated with a 5% BSA solution. An anti-digoxigenin-HRP antibody was then applied to the tissue sections and incubated at 37 °C for one hour. Finally, the DAB solution was used to develop the signal, which was then observed under a microscope. microRNA target reporter assay The target reporter assay was conducted following the protocols described in our previous studies [24, 25]. We synthesized two types of DNA sequences. One contained the predicted miR-212-5p binding sites within the 3′-untranslated region (3′-UTR) of Atf6, while the other was a null control sequence lacking these binding sites. These synthesized sequences were then subcloned into the 3′-UTR of the luciferase gene in the pMIR-REPORT luciferase plasmid. HEK293 cells were used for co-transfection. Each transfection mixture consisted of the constructed luciferase plasmids, the pMIR-REPORT β-gal Control Plasmid, and 200 nM of microRNA mimics. The microRNA mimics were either negative control mimics or mmu-miR-212-5p mimics. After transfection, the luciferase activity and β-galactosidase activity were measured using the Luciferase Assay System and β-galactosidase Enzyme Assay System from Promega, respectively. To account for variations in transfection efficiency and cell viability, the luciferase activity was normalized to the β-galactosidase activity. Comparative analysis was carried out by calculating the ratio of the normalized values between the miR-212-5p mimic group and the negative control mimic group. Immunofluorescence staining Paraffin-embedded kidney sections or cultured BUMPT cells were processed through a series of procedures. First, deparaffinization and rehydration were carried out. Antigen retrieval was achieved by incubating the samples in 0.1 M sodium citrate buffer (pH 6.0) at 100 °C. After antigen retrieval, the kidney sections or fixed cells were treated with 0.1% Triton X-100 to make the cell membranes permeable. Subsequently, they were placed in a blocking buffer to prevent non-specific antibody binding. The prepared samples were then incubated with the relevant primary antibody at 4 °C overnight. After washing, FITC-or rhodamine-conjugated secondary antibodies were applied and incubated for 1 h at room temperature. Finally, the samples were stained with DAPI (MilliporeSigma, D9542) to visualize the nuclei. All stained specimens were examined under a fluorescence microscope for further analysis. Immunohistochemical staining Paraffin-embedded kidney tissue sections were first subjected to deparaffinization. To retrieve the antigens, the sections were incubated in 0.1 M sodium citrate solution (pH 6.0) at 65 °C. Subsequently, a series of treatments were carried out. The slides were treated with 3% H₂O₂ to inhibit the activity of endogenous peroxidase. To minimize non-specific binding, they were then placed in a buffer solution containing 5% bovine serum albumin (BSA) and 0.1% Triton X-100.The sections were incubated with a specific primary antibody at 4 °C throughout the night. After that, a horseradish peroxidase (HRP)-conjugated secondary antibody was applied and incubated for 1 h at room temperature. The antigen-antibody complexes were visualized using a DAB kit according to the manufacturer’s instructions. Finally, the slides were counterstained with hematoxylin. Statistical analysis All data are presented as mean ± standard deviation (SD) from at least three independent experiments. Normality was assessed before conducting any comparisons. For comparisons among two groups, an unpaired, two-tailed Student’s t-test was used. For experiments involving three or more groups, one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was applied to assess differences between group means. Each treatment group had its own concurrent control, and no paired tests were performed. A p value < 0.05 was considered statistically significant. Analyses were conducted using GraphPad Prism 10.0 and SPSS 22.0. Results CsA could promote renal fibrosis both in vivo and in vitro models At first, we illustrated the effects of CsA on renal fibrosis progression in vivo. Histological analysis of kidney tissue, stained with Masson’s trichrome, revealed a marked increase in collagen deposition in CsA-treated mice compared to the control group (Fig. 1A-B). Specifically, the renal cortex of CsA-treated mice showed significantly thicker fibrotic areas, indicative of enhanced extracellular matrix (ECM) accumulation. In addition, immunohistochemical staining for fibronectin (Fn), α-smooth muscle actin (α-SMA), collagen type I (Col-I) and collagen type IV (Col-IV) revealed an increased expression of these markers in the CsA-treated kidneys (Fig. 1A), further supporting the activation of fibroblasts and myofibroblasts, which play a crucial role in fibrosis. Western blot analysis further confirmed the upregulation of these key fibrotic markers (Fig. 1C-D). Further, we also found the mRNA levels of chronic profibrotic factors (including Col1a1, Col4a1, Tgfb, Ctgf and Fgf2) were also significantly elevated, as shown by qPCR results (Fig. 1E), indicating a pro-fibrotic shift in gene expression. To further investigate the effects of CsA on renal fibrosis at the cellular level, BUMPT cells were treated with varying times of CsA (8 µM). The fibrotic phenotype of BUMPT cells treated with CsA exhibited a time-dependent increase. Morphological analysis showed that the cells progressively adopted a spindle-shaped, fibroblast-like appearance over time, with the most pronounced changes observed after 48 h of CsA treatment (Fig. 1F). Immunofluorescence staining for Fn further confirmed these findings, revealing a marked enhancement in Fn expression over time, with fluorescence intensity reaching its peak at the 48-hour time point (Fig. 1G). Western blot analysis confirmed that CsA treatment significantly increased the expression of fibrotic markers, including α-SMA and Fn, compared to the untreated control group (Fig. 1H-I). Additionally, quantitative qPCR showed upregulated mRNA levels of Tgfb, Ctgf and Fgf2 (Fig. 1J), key regulators of EMT, in CsA-treated cells. Our findings confirm that CsA induces renal fibrosis by promoting ECM deposition and activating fibrotic pathways in renal cells. This highlights the potential renal toxicity of CsA, especially in the context of long-term therapy. Fig. 1CsA could promote renal fibrosis both in vivo and in vitro models. (A-E) Eight-week-old C57BL/6J mice were administered either olive oil (5 ml/kg) or olive oil-suspended CsA (30 mg/kg) by gavage once a day for 2 weeks. Then, the mice were euthanized for further analysis. (A) representative images of Masson staining, immunohistochemical images of α-smooth muscle actin (α-SMA), fibronectin (Fn), collagen type I (Col-I) and collagen type IV (Col-IV), scale bar: 50 μm. (B) quantitative analysis of Masson staining images from (A). Data are presented as mean ± SD (n = 5, 2-tailed Student’s t test, *p < 0.05, compared with control). (C) Western blot analysis to visualize the expression levels of α-SMA, Fn; Col-I and Col-IV, GAPDH as the loading control. (D) Densitometric quantification of α-SMA, Fn; Col-I and Col-IV. In the control group, the ratio of α-SMA/GAPDH, FN/GAPDH, Col-I/ GAPDH and Col-IV/ GAPDH was set as 1.0, and the values of other experimental groups were normalized accordingly. All data are presented as mean ± SD (n = 4, 2-tailed Student’s t test). *p < 0.05 indicates a significant difference. (E) qPCR analysis showing the expression of Col1a1, Col4a1, Tgfb, Ctgf and Fgf2 during CsA treatment. Data are expressed as mean ± SD (n = 5, 2-tailed Student’s t test), *P < 0.05 indicates a significant difference. (F-J) BUMPT cells were either untreated (control) or exposed to 8 µM CsA for varying times. Post-treatment, cell morphology was recorded, and lysates were collected for immunoblot analysis. (F) Cell morphology images under light microscopy, scale bar: 20 μm. (G) Immunofluorescence images showing the expression of FN. scale bar: 20 μm. (H) Western blot analysis to visualize the expression levels of FN and α-SMA; GAPDH as the loading control. (I) Densitometric quantification of α-SMA and FN. In the control group, the ratio of α-SMA/GAPDH and FN/GAPDH was set as 1.0, and the values of other experimental groups were normalized accordingly. All data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05 indicates a significant difference. (J) qPCR analysis showing the expression of, Tgfb, Ctgf and Fgf2 during CsA treatment. Data are expressed as mean ± SD (n = 5, 1-way ANOVA with Tukey’s multiple comparisons test), *P < 0.05 indicates a significant difference CsA could promote renal fibrosis both in vivo and in vitro models. (A-E) Eight-week-old C57BL/6J mice were administered either olive oil (5 ml/kg) or olive oil-suspended CsA (30 mg/kg) by gavage once a day for 2 weeks. Then, the mice were euthanized for further analysis. (A) representative images of Masson staining, immunohistochemical images of α-smooth muscle actin (α-SMA), fibronectin (Fn), collagen type I (Col-I) and collagen type IV (Col-IV), scale bar: 50 μm. (B) quantitative analysis of Masson staining images from (A). Data are presented as mean ± SD (n = 5, 2-tailed Student’s t test, *p < 0.05, compared with control). (C) Western blot analysis to visualize the expression levels of α-SMA, Fn; Col-I and Col-IV, GAPDH as the loading control. (D) Densitometric quantification of α-SMA, Fn; Col-I and Col-IV. In the control group, the ratio of α-SMA/GAPDH, FN/GAPDH, Col-I/ GAPDH and Col-IV/ GAPDH was set as 1.0, and the values of other experimental groups were normalized accordingly. All data are presented as mean ± SD (n = 4, 2-tailed Student’s t test). *p < 0.05 indicates a significant difference. (E) qPCR analysis showing the expression of Col1a1, Col4a1, Tgfb, Ctgf and Fgf2 during CsA treatment. Data are expressed as mean ± SD (n = 5, 2-tailed Student’s t test), *P < 0.05 indicates a significant difference. (F-J) BUMPT cells were either untreated (control) or exposed to 8 µM CsA for varying times. Post-treatment, cell morphology was recorded, and lysates were collected for immunoblot analysis. (F) Cell morphology images under light microscopy, scale bar: 20 μm. (G) Immunofluorescence images showing the expression of FN. scale bar: 20 μm. (H) Western blot analysis to visualize the expression levels of FN and α-SMA; GAPDH as the loading control. (I) Densitometric quantification of α-SMA and FN. In the control group, the ratio of α-SMA/GAPDH and FN/GAPDH was set as 1.0, and the values of other experimental groups were normalized accordingly. All data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05 indicates a significant difference. (J) qPCR analysis showing the expression of, Tgfb, Ctgf and Fgf2 during CsA treatment. Data are expressed as mean ± SD (n = 5, 1-way ANOVA with Tukey’s multiple comparisons test), *P < 0.05 indicates a significant difference miR-212-5p was induced in CsA-induced renal fibrosis in mice As is well known, miRNAs are small non-coding RNAs that exert post-transcriptional control by binding to the 3′ untranslated region (UTR) of target mRNAs, leading to mRNA degradation or translational inhibition [26]. Thus, to pinpoint specific miRNAs involved in the development of CsA induced renal fibrosis, we harvested kidney cortical tissues from the CsA-treated mice to conduct a microarray analysis of miRNA expression. This analysis identified a series of miRNAs with altered expression levels (Fig. 2A). Based on the results of miRNA sequencing, we used qPCR to verify these differentially expressed miRNAs one by one. Finally, we found that the expression of miR-212-5p was stably upregulated in the kidneys of CsA-treated mice compared to control mice (Fig. 2B). In addition, our In situ hybridization analysis further verified that CsA-induced induction of miR-212-5p occurred primarily in the renal tubules within the cortex (Fig. 2C). Fig. 2miR-212-5p was induced in CsA-induced renal fibrosis in mice. Eight-week-old C57BL/6J mice were administered either olive oil (5 ml/kg) or olive oil-suspended CsA (30 mg/kg) by gavage once a day for 2 weeks. Then, the mice were euthanized for further analysis. (A) Microarray analysis was conducted to examine miRNA expression in the kidneys. Each row corresponds to a different miRNA, while each column represents an individual mouse sample. Downregulated miRNAs are shown in blue, whereas upregulated miRNAs are depicted in red. (B) qPCR validation showing significantly increased miR-212-5p expression in kidneys of CsA-treated mice. Expression levels were normalized to U6 small nuclear RNA (internal control), with the control group set as 1. Data are presented as mean ± SD (n = 6, 2-tailed Student’s t test). *p < 0.05 vs. control. (C) In situ hybridization demonstrating miR-212-5p induction in renal tissues following CsA treatment. Lower panels show high-magnification views of the boxed regions in upper panels. Scale bar: 50 μm miR-212-5p was induced in CsA-induced renal fibrosis in mice. Eight-week-old C57BL/6J mice were administered either olive oil (5 ml/kg) or olive oil-suspended CsA (30 mg/kg) by gavage once a day for 2 weeks. Then, the mice were euthanized for further analysis. (A) Microarray analysis was conducted to examine miRNA expression in the kidneys. Each row corresponds to a different miRNA, while each column represents an individual mouse sample. Downregulated miRNAs are shown in blue, whereas upregulated miRNAs are depicted in red. (B) qPCR validation showing significantly increased miR-212-5p expression in kidneys of CsA-treated mice. Expression levels were normalized to U6 small nuclear RNA (internal control), with the control group set as 1. Data are presented as mean ± SD (n = 6, 2-tailed Student’s t test). *p < 0.05 vs. control. (C) In situ hybridization demonstrating miR-212-5p induction in renal tissues following CsA treatment. Lower panels show high-magnification views of the boxed regions in upper panels. Scale bar: 50 μm ATF6 was silenced in CsA-induced renal fibrosis To Further identify molecular drivers in CsA-induced renal fibrosis, we performed transcriptomic profiling of the renal cortex from control and CsA-treated mice (n = 3 per group). This analysis revealed differentially expressed genes (DEGs), including upregulated and downregulated transcripts. Pathway enrichment analysis highlighted significant dysregulation of ER stress-related pathways, the UPR, and extracellular matrix organization. Among the downregulated genes, Atf6 emerged as a consistently suppressed UPR component (Fig. 3A), prompting our focused investigation of its role. ATF6 is a crucial component of the UPR that plays a central role in ER stress. Under normal conditions, it is maintained in an inactive state through its interaction with the ER chaperone Binding immunoglobulin Protein (BIP). However, during ER stress, BIP dissociates from ATF6 to assist in protein folding, leading to the activation of ATF6. Once activated, ATF6 translocate to the Golgi apparatus, where it is cleaved by site-1 and site-2 proteases. The cleaved cytoplasmic domain of ATF6 then translocate to the nucleus and binds to specific DNA sequences known as ER stress response elements (ERSEs) in the promoter regions of target genes. This binding activates the transcription of genes involved in restoring ER homeostasis, such as those encoding ER chaperones, folding enzymes, and components of the ER-associated degradation (ERAD) pathway [27–30]. Then, to further explore the role of ATF6 in CsA-induced renal fibrosis, we performed Western blot analysis on kidney tissue samples. The results showed a significant downregulation of ATF6 expression in CsA-treated mice compared to the control group (Fig. 3B-C). This finding was further confirmed by immunofluorescence staining, which revealed a significant reduction in ATF6-positive cells in the renal tissue of CsA-treated mice, particularly in tubular areas associated with fibrosis (Fig. 3D). Similarly, in cultured BUMPT cells, Western blot analysis demonstrated a marked downregulation of ATF6 protein expression following CsA treatment (Fig. 3E-F). Immunofluorescence staining of CsA-treated BUMPT cells also showed diminished ATF6 fluorescence intensity (Fig. 3G), supporting the Western blot results and indicating that CsA treatment disrupts ATF6 signaling in renal tubular cells. Together, these findings suggest that the downregulation of ATF6 plays a role in CsA-induced renal fibrosis and may be a key component of the ER stress response in renal tubular cells during fibrosis progression. Fig. 3ATF6 was silenced in CsA-induced renal fibrosis. (A–D) Eight-week-old C57BL/6J mice were administered either olive oil (5 ml/kg) or olive oil-suspended CsA (30 mg/kg) by gavage once a day for 2 weeks. Then, the mice were euthanized for further analysis. (A) Transcriptomic results of CsA-treated mice and control mice. Each row corresponds to a different mRNA, while each column represents an individual mouse sample. Downregulated mRNAs are shown in blue, whereas upregulated mRNAs are depicted in red. (B) Western blot analysis was carried out to visualize the expression levels of ATF6; GAPDH as the loading control. (C) Densitometric quantification of ATF6. In the control group, the ratio of ATF6/GAPDH was set as 1.0. All data are presented as mean ± SD (n = 4, 2-tailed Student’s t test). *p < 0.05 is statistically significant. (D) Immunofluorescence images showing the expression of ATF6. scale bar: 50 μm. (E–F) BUMPT cells were either untreated (control) or exposed to 8 µM CsA for 48 h. Post-treatment, the cells were collected for further analysis. (E) Western blot analysis was carried out to visualize the expression levels of ATF6; GAPDH as the loading control. (F) Densitometric quantification of ATF6. In the control group, the ratio of ATF6/GAPDH was set as 1.0. All data are presented as mean ± SD (n = 4, 2-tailed Student’s t test). *p < 0.05 is statistically significant. (G) Immunofluorescence images showing the expression of ATF6. scale bar: 20 μm ATF6 was silenced in CsA-induced renal fibrosis. (A–D) Eight-week-old C57BL/6J mice were administered either olive oil (5 ml/kg) or olive oil-suspended CsA (30 mg/kg) by gavage once a day for 2 weeks. Then, the mice were euthanized for further analysis. (A) Transcriptomic results of CsA-treated mice and control mice. Each row corresponds to a different mRNA, while each column represents an individual mouse sample. Downregulated mRNAs are shown in blue, whereas upregulated mRNAs are depicted in red. (B) Western blot analysis was carried out to visualize the expression levels of ATF6; GAPDH as the loading control. (C) Densitometric quantification of ATF6. In the control group, the ratio of ATF6/GAPDH was set as 1.0. All data are presented as mean ± SD (n = 4, 2-tailed Student’s t test). *p < 0.05 is statistically significant. (D) Immunofluorescence images showing the expression of ATF6. scale bar: 50 μm. (E–F) BUMPT cells were either untreated (control) or exposed to 8 µM CsA for 48 h. Post-treatment, the cells were collected for further analysis. (E) Western blot analysis was carried out to visualize the expression levels of ATF6; GAPDH as the loading control. (F) Densitometric quantification of ATF6. In the control group, the ratio of ATF6/GAPDH was set as 1.0. All data are presented as mean ± SD (n = 4, 2-tailed Student’s t test). *p < 0.05 is statistically significant. (G) Immunofluorescence images showing the expression of ATF6. scale bar: 20 μm ATF6 was the target of miR-212-5p As is well known, miRNAs are small non-coding RNAs that exert post-transcriptional control by binding to the 3′UTR of target mRNAs, leading to mRNA degradation or translational inhibition [26]. Given the concurrent upregulation of miR-212-5p and downregulation of ATF6 in CsA-treated kidneys, we hypothesized that ATF6 might be a direct target of miR-212-5p; therefore, we further investigated whether miR-212-5p directly regulates ATF6 expression through this canonical mechanism. We employed online bioinformatics databases (TargetScan, available at http://www.targetscan.org/vert_72/) for analysis. This process led to the discovery of a potential miR-212-5p targeting site within the 3′-UTR of mouse Atf6 mRNA (Fig. 4A). Strikingly, this targeting sequence exhibits a high degree of conservation across various animal species, as presented in Fig. 4B. To ascertain whether ATF6 truly serves as a target of miR-212-5p, we initially examined the influence of miR-212-5p on ATF6 expression. In vivo, immunoblot analysis revealed that CsA treatment significantly reduced ATF6 protein levels in mouse kidneys. Moreover, tail vein delivery of a miR-212-5p mimic further suppressed ATF6 expression compared to CsA treatment alone. Strikingly, this enhanced downregulation of ATF6 was accompanied by a concomitant increase in the fibrosis markers α-SMA and Fn, which exhibited an opposite trend to ATF6 (Fig. 4C–D). Consistent with the immunoblot analysis, immunofluorescence findings further supported the inhibitory effect of miR-212-5p. Transfection of miR-212-5p mimic into mice exposed to CsA resulted in a notable reduction in ATF6 expression (Fig. 4E). Notably, in vitro experiments showed that CsA treatment also suppressed ATF6 expression in cultured BUMPT cells. Consistent with the in vivo findings, this reduction was further exacerbated by transfection with a miR-212-5p mimic, as demonstrated by both immunoblot (Fig. 4F-G) and immunofluorescence staining (Fig. 4H). Importantly, Western blotting revealed that the miR-212-5p–mediated downregulation of ATF6 was accompanied by a concomitant upregulation of the fibrosis markers α-SMA and Fn. To determine if ATF6 is a direct target of miR-212-5p, we conducted a luciferase microRNA target reporter assay. The 3′-UTR sequence of Atf6 was cloned into a microRNA Luciferase reporter construct. Subsequently, this construct was co-transfected with either miR-212-5p mimic or negative control (NC) oligonucleotides into HEK293 cells. As depicted in Fig. 4I, co-transfection with miR-212-5p mimic (but not the NC oligonucleotides) led to a significant suppression of luciferase expression from the reporter construct containing the Atf6 3′-UTR. In addition, we also examined key markers of the PERK and IRE1 pathways, including phospho-PERK and spliced XBP1 (XBP1s). As shown in Supplementary Fig. 1, CsA treatment activated these branches, but modulation of anti-miR-212-5p did not significantly alter their activity, indicating that miR-212-5p specifically targets the ATF6 arm of the UPR without affecting PERK or IRE1 signaling. Taken together, these results strongly suggest that miR-212-5p can directly target ATF6 mRNA, thereby repressing its expression in CsA-induced renal fibrosis. Fig. 4ATF6 was the target of miR-212-5p. (A-B) Schematic representation of the conserved miR-212-5p binding site within the 3′-UTR of Atf6 mRNA. (C) Western blot analysis showing ATF6, α-SMA and FN protein expression; GAPDH served as a loading control. Experimental design: Eight-week-old C57BL/6J mice received daily gavage of olive oil (5 ml/kg) or CsA (30 mg/kg in olive oil) for 2 weeks. Some mice were co-administered miR-212-5p mimic (3 mg/kg) or negative control (NC) oligonucleotides via tail vein injection every 2 days until 1 day prior to sacrifice. (D) Densitometric quantification of ATF6, α-SMA and FN protein levels, normalized to GAPDH (control group = 1.0). Data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05. (E) Immunofluorescence staining revealing the inhibitory effect of miR-212-5p on ATF6 expression in renal tissues (experimental conditions as in C). Scale bar: 50 μm. (F) Western blot analysis showing ATF6, α-SMA and FN protein expression; GAPDH served as a loading control. Experimental design: Cells were transfected with 200 nM miR-212-5p mimic or NC for 24 h, followed by treatment with or without 8 µM CsA for 48 h. (G) Densitometric quantification of ATF6, α-SMA and FN protein levels, normalized to GAPDH (control group = 1.0). Data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05. (H) Immunofluorescence analysis demonstrating miR-212-5p-mediated suppression of ATF6 in BUMPT cells. Scale bar: 20 μm.(I) miRNA target reporter assay verifying direct binding of miR-212-5p to Atf6 3′-UTR. The putative miR-212-5p binding sequence in Atf6 3′-UTR was cloned into the pMIR-REPORT vector. Luciferase activity was measured after co-transfection with miR-212-5p mimic or NC oligonucleotides, showing specific reduction with miR-212-5p mimic. Data are presented as mean ± SD (n = 6, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05 ATF6 was the target of miR-212-5p. (A-B) Schematic representation of the conserved miR-212-5p binding site within the 3′-UTR of Atf6 mRNA. (C) Western blot analysis showing ATF6, α-SMA and FN protein expression; GAPDH served as a loading control. Experimental design: Eight-week-old C57BL/6J mice received daily gavage of olive oil (5 ml/kg) or CsA (30 mg/kg in olive oil) for 2 weeks. Some mice were co-administered miR-212-5p mimic (3 mg/kg) or negative control (NC) oligonucleotides via tail vein injection every 2 days until 1 day prior to sacrifice. (D) Densitometric quantification of ATF6, α-SMA and FN protein levels, normalized to GAPDH (control group = 1.0). Data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05. (E) Immunofluorescence staining revealing the inhibitory effect of miR-212-5p on ATF6 expression in renal tissues (experimental conditions as in C). Scale bar: 50 μm. (F) Western blot analysis showing ATF6, α-SMA and FN protein expression; GAPDH served as a loading control. Experimental design: Cells were transfected with 200 nM miR-212-5p mimic or NC for 24 h, followed by treatment with or without 8 µM CsA for 48 h. (G) Densitometric quantification of ATF6, α-SMA and FN protein levels, normalized to GAPDH (control group = 1.0). Data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05. (H) Immunofluorescence analysis demonstrating miR-212-5p-mediated suppression of ATF6 in BUMPT cells. Scale bar: 20 μm.(I) miRNA target reporter assay verifying direct binding of miR-212-5p to Atf6 3′-UTR. The putative miR-212-5p binding sequence in Atf6 3′-UTR was cloned into the pMIR-REPORT vector. Luciferase activity was measured after co-transfection with miR-212-5p mimic or NC oligonucleotides, showing specific reduction with miR-212-5p mimic. Data are presented as mean ± SD (n = 6, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05 Inhibiting miR-212-5p could attenuate CsA-induced renal fibrosis To further explore the role of miR-212-5p in CsA-induced renal fibrosis, we investigated the effects of anti–miR-212-5p. Locked nucleic acid-modified (LNA-modified) anti-miR-212-5p or scrambled sequence oligonucleotides (NC) were administered to mice through tail vein injection. Masson’s trichrome staining of kidney tissues showed a significant reduction in collagen deposition in the anti-miR-212-5p-treated group compared to the CsA-only group (Fig. 5A and D). Immunohistochemical analysis further revealed that the expression of α-SMA and Fn was significantly reduced in the anti-miR-212-5p group compared to the CsA-only group (Fig. 5B-C). Western blot analysis demonstrated that anti-miR-212-5p treatment significantly downregulated the protein expression levels of α-SMA and Fn in kidney tissues, aligning with the histological findings (Fig. 5E-F). qPCR analysis further revealed that the mRNA levels of key pro-fibrotic mediators, including Tgfb, Ctgf, and Fgf2, were significantly reduced in the anti-miR-212-5p group compared to the CsA-only group (Fig. 5G-I). To further confirm the role of miR-212-5p in CsA-induced renal fibrosis, BUMPT cells were treated with anti-miR-212-5p. Morphological analysis revealed that anti-miR-212-5p treatment largely preserved the epithelial morphology of the cells (Fig. 6A), indicating a protective effect against CsA-induced fibrotic transformation. Immunofluorescence staining for Fn showed a substantial increase in Fn expression following CsA treatment, whereas anti-miR-212-5p significantly reduced Fn fluorescence intensity (Fig. 6B). This suggests that anti-miR-212-5p effectively suppresses extracellular matrix production induced by CsA. Western blot analysis demonstrated that anti-miR-212-5p treatment significantly downregulated the protein levels of fibrotic markers α-SMA and Fn compared to CsA-only treated cells (Fig. 6C-D). Consistent with these findings, qPCR analysis revealed a marked reduction in the mRNA levels of key pro-fibrotic mediators, including Tgfb, Ctgf, and Fgf2, in the anti-miR-212-5p-treated group (Fig. 6E-G). Taking together, these findings suggest that inhibition of miR-212-5p by anti-miR-212-5p effectively alleviates CsA-induced renal fibrosis by reducing collagen deposition, myofibroblast activation, extracellular matrix production, and pro-fibrotic gene expression. This highlights the potential therapeutic value of targeting miR-212-5p in mitigating renal fibrosis. Fig. 5Inhibiting miR-212-5p could attenuate CsA-induced renal fibrosis in mice. Eight-week-old C57BL/6J mice were administered either olive oil (5 ml/kg) or olive oil-suspended CsA (30 mg/kg) by gavage once a day for 2 weeks. In some mice, anti-miR-212-5p LNA(6 mg/Kg) or negative control (NC) oligonucleotide were delivered to mice through tail vein injection every 2 days till the day before the mice were sacrificed. (A) representative images of Masson staining, scale bar: 50 μm. (B) Representative immunohistochemical images of α-SMA, scale bar: 50 μm. (C) Representative immunohistochemical images of FN, scale bar: 50 μm. (D) quantitative analysis of Masson staining images from (A). Data are presented as mean ± SD (n = 5, 1-way ANOVA with Tukey’s multiple comparisons test, *p < 0.05). (E) Western blot analysis was carried out to visualize the expression levels of FN, α-SMA and ATF6; GAPDH as the loading control. (F) Densitometric quantification of FN, α-SMA and ATF6. In the NC group, the ratio of α-SMA/GAPDH, FN/GAPDH and ATF6/GAPDH was set as 1.0, and the values of other experimental groups were normalized accordingly. All data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05 indicates a significant difference. (G-I) qPCR analysis showing the expression of Tgfb, Ctgf and Fgf2 expression. Data are expressed as mean ± SD (n = 5, 1-way ANOVA with Tukey’s multiple comparisons test), *P < 0.05 indicates a significant difference Inhibiting miR-212-5p could attenuate CsA-induced renal fibrosis in mice. Eight-week-old C57BL/6J mice were administered either olive oil (5 ml/kg) or olive oil-suspended CsA (30 mg/kg) by gavage once a day for 2 weeks. In some mice, anti-miR-212-5p LNA(6 mg/Kg) or negative control (NC) oligonucleotide were delivered to mice through tail vein injection every 2 days till the day before the mice were sacrificed. (A) representative images of Masson staining, scale bar: 50 μm. (B) Representative immunohistochemical images of α-SMA, scale bar: 50 μm. (C) Representative immunohistochemical images of FN, scale bar: 50 μm. (D) quantitative analysis of Masson staining images from (A). Data are presented as mean ± SD (n = 5, 1-way ANOVA with Tukey’s multiple comparisons test, *p < 0.05). (E) Western blot analysis was carried out to visualize the expression levels of FN, α-SMA and ATF6; GAPDH as the loading control. (F) Densitometric quantification of FN, α-SMA and ATF6. In the NC group, the ratio of α-SMA/GAPDH, FN/GAPDH and ATF6/GAPDH was set as 1.0, and the values of other experimental groups were normalized accordingly. All data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05 indicates a significant difference. (G-I) qPCR analysis showing the expression of Tgfb, Ctgf and Fgf2 expression. Data are expressed as mean ± SD (n = 5, 1-way ANOVA with Tukey’s multiple comparisons test), *P < 0.05 indicates a significant difference Fig. 6Inhibiting miR-212-5p could attenuate CsA-induced renal fibrosis in cultured BUMPT cells. BUMPT cells were transfected with 200 nM anti-miR-212-5p LNA or NC for 24 h, followed by treatment with or without 8 µM CsA for 48 h. (A) Cell morphology images under light microscopy, scale bar: 20 μm. (B) Immunofluorescence images showing the expression of FN. scale bar: 20 μm. (C) Western blot analysis was carried out to visualize the expression levels of FN, α-SMA and ATF6; GAPDH as the loading control. (D) Densitometric quantification of FN, α-SMA and ATF6. In the NC group, the ratio of α-SMA/GAPDH, FN/GAPDH and ATF6/GAPDH was set as 1.0, and the values of other experimental groups were normalized accordingly. All data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05 indicates a significant difference (E-G) qPCR analysis showing the expression of Tgfb, Ctgf and Fgf2. Data are expressed as mean ± SD (n = 5, 1-way ANOVA with Tukey’s multiple comparisons test), *P < 0.05 indicates a significant difference Inhibiting miR-212-5p could attenuate CsA-induced renal fibrosis in cultured BUMPT cells. BUMPT cells were transfected with 200 nM anti-miR-212-5p LNA or NC for 24 h, followed by treatment with or without 8 µM CsA for 48 h. (A) Cell morphology images under light microscopy, scale bar: 20 μm. (B) Immunofluorescence images showing the expression of FN. scale bar: 20 μm. (C) Western blot analysis was carried out to visualize the expression levels of FN, α-SMA and ATF6; GAPDH as the loading control. (D) Densitometric quantification of FN, α-SMA and ATF6. In the NC group, the ratio of α-SMA/GAPDH, FN/GAPDH and ATF6/GAPDH was set as 1.0, and the values of other experimental groups were normalized accordingly. All data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05 indicates a significant difference (E-G) qPCR analysis showing the expression of Tgfb, Ctgf and Fgf2. Data are expressed as mean ± SD (n = 5, 1-way ANOVA with Tukey’s multiple comparisons test), *P < 0.05 indicates a significant difference Inhibiting ER stress could attenuate CsA-induced renal fibrosis Given our finding that miR-212-5p is upregulated in CsA-induced renal fibrosis and directly targets Atf6, a key mediator of the adaptive UPR, we next sought to determine whether pharmacological inhibition of ER stress could counteract fibrotic progression. We first assessed the activation status of ER stress in vivo. Immunohistochemical analysis revealed markedly increased expression of the canonical ER stress markers BiP and C/EBP Homologous Protein (CHOP) in kidney tissues from CsA-treated mice compared to controls. Notably, both proteins were predominantly localized in renal tubular epithelial cells, colocalizing with areas of fibrotic lesion formation (Fig. 7A). Western blot analysis further confirmed significant upregulation of BiP and CHOP at the protein level (Fig. 7B–C), indicating robust activation of ER stress during CsA-induced nephropathy. To investigate whether modulating ER stress influences fibrogenesis, we administered 4-phenylbutyric acid (4-PBA), a well-established chemical chaperone that alleviates ER stress, to CsA-treated mice. Remarkably, Masson’s trichrome staining showed that co-treatment with 4-PBA significantly reduced collagen deposition in the renal cortex compared to the CsA-only group (Fig. 7D-E). Consistently, immunohistochemical staining demonstrated decreased expression of α-SMA and Fn, suggesting attenuated myofibroblast activation and ECM accumulation upon ER stress inhibition (Fig. 7D). These observations were corroborated by Western blot which revealed downregulated protein levels of α-SMA and Fn (Fig. 7F-G). Similarly, qPCR analysis demonstrated that the mRNA levels of key pro-fibrotic mediators, including Tgfb, Ctgf, and Fgf2, were significantly reduced in the 4-PBA + CsA group (Fig. 7H). Fig. 7Inhibiting ER-stress could attenuate CsA-induced renal fibrosis in mice. Eight-week-old C57BL/6J mice were administered either olive oil (5 ml/kg) or olive oil-suspended CsA (30 mg/kg) by gavage once a day for 2 weeks. 4-Phenylbutyric acid (4-PBA) was dissolved in saline and then administrated once daily by intraperitoneal injection with a dosage of 20 mg/kg till the day before sacrificing. Normal saline was injected as vehicle control. (A) Representative immunohistochemical images of Binding Immunoglobulin Protein (BiP) and C/EBP Homologous Protein (CHOP), scale bar: 50 μm. (B) Western blot analysis was carried out to visualize the expression levels of BIP and CHOP; GAPDH as the loading control. (C) Densitometric quantification of BIP and CHOP. In the control group, the ratio of BIP/GAPDH and CHOP/GAPDH was set as 1.0. All data are presented as mean ± SD (n = 4, 2-tailed Student’s t test). *p < 0.05 is statistically significant. (D) representative images of Masson staining, immunohistochemical images of α-SMA and Fn, scale bar: 50 μm. (E) quantitative analysis of Masson staining images from (D). Data are presented as mean ± SD (n = 5, 2-tailed Student’s t test, *p < 0.05). (F) Western blot analysis was carried out to visualize the expression levels of α-SMA, FN, BiP and CHOP; GAPDH as the loading control. (G) Densitometric quantification of α-SMA, FN, BiP and CHOP. In the control group, the ratio of Bip/GAPDH, CHOP/GAPDH, α-SMA /GAPDH and FN/GAPDH was set as 1.0, and the values of other experimental groups were normalized accordingly. All data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05 indicates a significant difference. (H) qPCR analysis showing the expression of T Tgfb, Ctgf and Fgf2 expression. Data are expressed as mean ± SD (n = 5, 1-way ANOVA with Tukey’s multiple comparisons test), *P < 0.05 indicates a significant difference Inhibiting ER-stress could attenuate CsA-induced renal fibrosis in mice. Eight-week-old C57BL/6J mice were administered either olive oil (5 ml/kg) or olive oil-suspended CsA (30 mg/kg) by gavage once a day for 2 weeks. 4-Phenylbutyric acid (4-PBA) was dissolved in saline and then administrated once daily by intraperitoneal injection with a dosage of 20 mg/kg till the day before sacrificing. Normal saline was injected as vehicle control. (A) Representative immunohistochemical images of Binding Immunoglobulin Protein (BiP) and C/EBP Homologous Protein (CHOP), scale bar: 50 μm. (B) Western blot analysis was carried out to visualize the expression levels of BIP and CHOP; GAPDH as the loading control. (C) Densitometric quantification of BIP and CHOP. In the control group, the ratio of BIP/GAPDH and CHOP/GAPDH was set as 1.0. All data are presented as mean ± SD (n = 4, 2-tailed Student’s t test). *p < 0.05 is statistically significant. (D) representative images of Masson staining, immunohistochemical images of α-SMA and Fn, scale bar: 50 μm. (E) quantitative analysis of Masson staining images from (D). Data are presented as mean ± SD (n = 5, 2-tailed Student’s t test, *p < 0.05). (F) Western blot analysis was carried out to visualize the expression levels of α-SMA, FN, BiP and CHOP; GAPDH as the loading control. (G) Densitometric quantification of α-SMA, FN, BiP and CHOP. In the control group, the ratio of Bip/GAPDH, CHOP/GAPDH, α-SMA /GAPDH and FN/GAPDH was set as 1.0, and the values of other experimental groups were normalized accordingly. All data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05 indicates a significant difference. (H) qPCR analysis showing the expression of T Tgfb, Ctgf and Fgf2 expression. Data are expressed as mean ± SD (n = 5, 1-way ANOVA with Tukey’s multiple comparisons test), *P < 0.05 indicates a significant difference Parallel experiments were conducted in cultured BUMPT cells to validate these findings at the cellular level. Treatment with CsA induced strong upregulation of BiP and CHOP, as shown by immunofluorescence and Western blot (Fig. 8A–C), confirming ER stress activation in renal tubular cells. Morphologically, CsA triggered an epithelial-to-mesenchymal transition (EMT)-like phenotype characterized by elongated, spindle-shaped cells—effects that were largely prevented by co-treatment with 4-PBA (Fig. 8D). Furthermore, 4-PBA significantly reduced CsA-induced Fn expression (Fig. 8E), suppressed α-SMA and Fn protein expression (Fig. 8F–G), and downregulated Tgfb, Ctgf, and Fgf2 mRNA levels (Fig. 7H). These results mirror the in vivo data and demonstrate that ameliorating ER stress effectively blocks the fibrotic cascade in renal tubular epithelial cells. Fig. 8Inhibiting ER-stress could attenuate CsA-induced renal fibrosis in cultured BUMPT cells. BUMPT cells were either untreated (control) or exposed to 8 µM CsA for 48 h. In some experiments, 1 mM of 4-PBA was added simultaneously with the treatment of CsA. Post-treatment, cell morphology was recorded, and lysates were collected for immunoblot analysis. (A) Immunofluorescence images showing the expression of Chop and Bip. scale bar: 50 μm. (B) Western blot analysis to visualize the expression levels of BIP and CHOP; GAPDH as the loading control. (C) Densitometric quantification of BIP and CHOP. In the control group, the ratio of BIP/GAPDH and CHOP/GAPDH was set as 1.0. All data are presented as mean ± SD (n = 4, 2-tailed Student’s t test). *p < 0.05 is statistically significant. (D) Cell morphology images under light microscopy, scale bar: 20 μm. (E) Immunofluorescence images showing the expression of Fn. scale bar: 20 μm. (F) Western blot analysis was carried out to visualize the expression levels of α-SMA, FN, BiP and CHOP; GAPDH as the loading control. (G) Densitometric quantification of α-SMA, FN, BiP and CHOP. In the control group, the ratio of Bip/GAPDH, CHOP/GAPDH, α-SMA /GAPDH and FN/GAPDH was set as 1.0, and the values of other experimental groups were normalized accordingly. All data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05 indicates a significant difference. (H) qPCR analysis showing the expression of Tgfb, Ctgf and Fgf2. Data are expressed as mean ± SD (n = 5, 1-way ANOVA with Tukey’s multiple comparisons test), *P < 0.05 indicates a significant difference Inhibiting ER-stress could attenuate CsA-induced renal fibrosis in cultured BUMPT cells. BUMPT cells were either untreated (control) or exposed to 8 µM CsA for 48 h. In some experiments, 1 mM of 4-PBA was added simultaneously with the treatment of CsA. Post-treatment, cell morphology was recorded, and lysates were collected for immunoblot analysis. (A) Immunofluorescence images showing the expression of Chop and Bip. scale bar: 50 μm. (B) Western blot analysis to visualize the expression levels of BIP and CHOP; GAPDH as the loading control. (C) Densitometric quantification of BIP and CHOP. In the control group, the ratio of BIP/GAPDH and CHOP/GAPDH was set as 1.0. All data are presented as mean ± SD (n = 4, 2-tailed Student’s t test). *p < 0.05 is statistically significant. (D) Cell morphology images under light microscopy, scale bar: 20 μm. (E) Immunofluorescence images showing the expression of Fn. scale bar: 20 μm. (F) Western blot analysis was carried out to visualize the expression levels of α-SMA, FN, BiP and CHOP; GAPDH as the loading control. (G) Densitometric quantification of α-SMA, FN, BiP and CHOP. In the control group, the ratio of Bip/GAPDH, CHOP/GAPDH, α-SMA /GAPDH and FN/GAPDH was set as 1.0, and the values of other experimental groups were normalized accordingly. All data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05 indicates a significant difference. (H) qPCR analysis showing the expression of Tgfb, Ctgf and Fgf2. Data are expressed as mean ± SD (n = 5, 1-way ANOVA with Tukey’s multiple comparisons test), *P < 0.05 indicates a significant difference Overexpression of ATF6 attenuates CsA-induced renal fibrosis To further substantiate that the pro-fibrotic effect of miR-212-5p is mediated through its direct suppression of ATF6, we asked whether restoring ATF6 expression despite elevated miR-212-5p levels could rescue renal tubular cells from CsA-induced injury. Given that miR-212-5p targets the 3′UTR of Atf6 and reduces both its mRNA and protein abundance, we hypothesized that forced expression of ATF6 lacking the native 3′UTR would bypass miR-212-5p-mediated repression and confer protection against fibrosis. To determine the functional role of ATF6 in CsA-induced renal fibrosis, ATF6 was overexpressed in cultured BUMPT cells via transfection with an ATF6 expression plasmid. Morphological analysis revealed that CsA-treated cells exhibited significant EMT-like changes, including an elongated, spindle-shaped appearance. In contrast, cells overexpressing ATF6 largely retained their epithelial cobblestone morphology, indicating that ATF6 overexpression mitigates CsA-induced cellular transformation (Fig. 9A). Immunofluorescence staining for Fn showed that CsA treatment led to a marked increase in Fn expression, whereas ATF6 overexpression significantly reduced Fn fluorescence intensity (Fig. 9B). Western blot analysis further supported these findings, showing that ATF6 overexpression significantly downregulated the protein levels of fibrotic markers α-SMA and Fn, compared to cells treated with CsA alone (Fig. 9C-D). Similarly, qPCR analysis demonstrated that overexpression of ATF6 significantly decreased the mRNA levels of key pro-fibrotic mediators, including Tgfb, Ctgf, and Fgf2 (Fig. 9E-G). Collectively, these results demonstrate that restoring ATF6 expression is sufficient to counteract CsA-induced fibrogenesis even in the presence of ongoing ER stress and elevated miR-212-5p. This not only confirms the protective function of ATF6 in renal tubular epithelial cells but also provides compelling functional evidence that miR-212-5p promotes renal fibrosis primarily through silencing ATF6. Together with our gain-of-function and loss-of-function studies of miR-212-5p, these data establish the miR-212-5p–ATF6 axis as a central regulatory node in CsA-induced renal fibrosis, highlighting its potential as a therapeutic target for mitigating calcineurin inhibitor-associated nephrotoxicity. Fig. 9Overexpression of ATF6 attenuates CsA-induced renal fibrosis in cultured BUMPT cells. BUMPT cells were transfected with 50 nM Atf6 plasmid or NC oligonucleotides and then treated with 8 µM CsA for 48 h. (A) Cell morphology images under light microscopy, scale bar: 20 μm. (B) Immunofluorescence images showing the expression of FN. scale bar: 20 μm. (C) Western blot analysis was carried out to visualize the expression levels of ATF6, α-SMA and Fn; GAPDH as the loading control. (D) Densitometric quantification of ATF6, α-SMA and FN. In the NC group, the ratio of ATF6/GAPDH, α-SMA/GAPDH and FN/GAPDH was set as 1.0, and the values of other experimental groups were normalized accordingly. All data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05 indicates a significant difference (E-G) qPCR analysis showing the expression of Tgfb, Ctgf and Fgf2. Data are expressed as mean ± SD (n = 5, 1-way ANOVA with Tukey’s multiple comparisons test), *P < 0.05 indicates a significant difference Overexpression of ATF6 attenuates CsA-induced renal fibrosis in cultured BUMPT cells. BUMPT cells were transfected with 50 nM Atf6 plasmid or NC oligonucleotides and then treated with 8 µM CsA for 48 h. (A) Cell morphology images under light microscopy, scale bar: 20 μm. (B) Immunofluorescence images showing the expression of FN. scale bar: 20 μm. (C) Western blot analysis was carried out to visualize the expression levels of ATF6, α-SMA and Fn; GAPDH as the loading control. (D) Densitometric quantification of ATF6, α-SMA and FN. In the NC group, the ratio of ATF6/GAPDH, α-SMA/GAPDH and FN/GAPDH was set as 1.0, and the values of other experimental groups were normalized accordingly. All data are presented as mean ± SD (n = 4, 1-way ANOVA with Tukey’s multiple comparisons test). *p < 0.05 indicates a significant difference (E-G) qPCR analysis showing the expression of Tgfb, Ctgf and Fgf2. Data are expressed as mean ± SD (n = 5, 1-way ANOVA with Tukey’s multiple comparisons test), *P < 0.05 indicates a significant difference Discussion The central finding of this study is the identification of miR-212-5p as a previously unrecognized molecular target of CsA, which acts as a master regulator in the development of CsA-induced renal fibrosis. We demonstrate that CsA treatment robustly upregulates miR-212-5p expression in renal tubular epithelial cells, and this elevation directly silences Atf6 mRNA, thereby disabling a critical adaptive arm of the UPR. This newly defined miR-212-5p/ATF6 axis serves as a pivotal mechanistic link between CsA exposure and the activation of maladaptive ER stress, ultimately driving excessive ECM deposition and tubulointerstitial fibrosis. CsA, a widely used immunosuppressant, is known to cause significant nephrotoxicity, including chronic CsA nephropathy, which is characterized by progressive renal fibrosis [2, 31]. For example, a recent study demonstrated that chronic CsA exposure increases the expression of key fibrosis markers via TGF-β1/SMAD2/3 pathway [2]. In our study, we observed that CsA treatment markedly promoted renal fibrosis, consistent with findings from multiple studies [1, 2, 31]. However, the precise molecular mechanisms, particularly the regulation of key UPR components, have remained elusive. Notably, transcriptomic analysis of CsA-treated renal tissues revealed a marked downregulation of Atf6 mRNA, indicating specific suppression of this critical adaptive UPR transcription factor during CsA injury. Given that miRNAs function as post-transcriptional repressors by binding to the 3′UTR of target mRNAs to induce degradation or translational inhibition [26], and considering their well-established roles in fibrosis and immune regulation [32, 33], we investigated whether a CsA-induced miRNA might mediate ATF6 suppression. We found that miR-212-5p is consistently upregulated by CsA and exhibits a strong inverse correlation with ATF6 expression. Bioinformatic prediction followed by dual-luciferase reporter assays and functional rescue experiments confirmed that Atf6 is a direct target of miR-212-5p. Specifically, miR-212-5p binds to a conserved site within the Atf6 3′UTR, resulting in post-transcriptional silencing of ATF6. In addition, to further validate the functional role of miR-212-5p in CsA-induced renal fibrosis, we performed loss-of-function experiments using anti-miR-212-5p. Inhibiting miR-212-5p with anti-miR-212-5p effectively alleviated CsA-induced renal fibrosis by reducing collagen deposition, myofibroblast activation, extracellular matrix production, and pro-fibrotic gene expression. Collectively, these findings establish miR-212-5p as a central pathogenic driver in CsA-induced renal injury. This newly identified miR-212-5p/ATF6 axis provides a mechanistic explanation for the progression of chronic CsA nephropathy and highlights a potential therapeutic target for mitigating CsA-associated kidney damage. In recent years, substantial progress has been made in understanding how ER-stress activation promotes renal fibrosis [34]. Research has shown that under pathological conditions like oxidative stress or nutrient deprivation, ER-stress is activated in various renal cell types [34]. It triggers the UPR, which, when over-activated, can dysregulate gene expression related to ECM metabolism [34]. ER-stress also induces EMT in tubular epithelial cells and promotes inflammation and apoptosis in renal cells. These processes contribute to enhanced ECM deposition and myofibroblast activation, ultimately leading to renal fibrosis [15, 16]. ATF6 is a crucial component of the UPR that plays a central role in ER stress. Under normal conditions, it is maintained in an inactive state through its interaction with the ER chaperone BIP. However, during ER stress, BIP dissociates from ATF6 to assist in protein folding, leading to the activation of ATF6. Once activated, ATF6 translocate to the Golgi apparatus, where it is cleaved by site-1 and site-2 proteases. The cleaved cytoplasmic domain of ATF6 then translocate to the nucleus and binds to specific DNA sequences known as ER stress response elements (ERSEs) in the promoter regions of target genes. This binding activates the transcription of genes involved in restoring ER homeostasis, such as those encoding ER chaperones, folding enzymes, and components of the ER-associated degradation (ERAD) pathway [27–30]. Based on the provided literature, current evidence does not support a general reduction in ATF6 levels during renal fibrosis; instead, its role appears context dependent. Transcriptomic analyses of fibrotic kidneys from patients with CKD and various murine injury models consistently show the activation of ER stress pathways [35]. Furthermore, research has demonstrated that the ER-resident protein TXNDC5, a critical mediator of fibrosis, is transcriptionally upregulated via the ATF6-dependent branch of the ER stress response in kidney fibroblasts [12]. This indicates active involvement of the ATF6 signaling axis in promoting fibrogenic responses. However, functional genetic studies using murine models suggest that the PERK arm of ER stress, rather than ATF6 or IRE1, is the dominant pathway driving fibrotic progression [35]. Therefore, a decrease in ATF6 levels observed specifically in a CsA-induced model likely represents a distinct, agent-specific pathological mechanism or a compensatory feedback regulation, rather than a universal hallmark of renal fibrosis. The general feature across fibrotic contexts appears to be the activation of ER stress, with varying contributions from its different branches. Our results showed that the downregulation of ATF6 in CsA-induced renal fibrosis may contribute to the over-activation of ER stress. Overexpression of ATF6 in cultured BUMPT cells mitigated CsA-induced renal fibrosis by reducing EMT-like morphological changes, extracellular matrix production, and pro-fibrotic gene expression. This suggests that ATF6 plays a protective role in counteracting the fibrotic effects of CsA in renal tubular epithelial cells. In addition, it is noteworthy that our study identifies miR-212-5p as a CsA-upregulated miRNA that directly targets ATF6, whereas this miRNA was not reported in the earlier profiling study by Gooch et al. (2017) [36]. This discrepancy likely stems from key methodological and biological differences between the two studies. Although both used C57BL/6 mice and similar CsA dosing (20 mg/kg/day), Gooch et al. analyzed whole-kidney tissue after six weeks of treatment with a focus on early histological features such as periarterial inflammation and collagen IV upregulation, whereas our model emphasizes established tubulointerstitial fibrosis, as evidenced by robust Masson trichrome staining and elevated expression of collagen and α-SMA. Furthermore, Gooch et al. employed a microRNA microarray platform covering approximately 1900 mouse miRNAs, while we used small RNA sequencing, which offers greater sensitivity, a broader dynamic range, and improved detection of low-abundance or less-conserved miRNAs such as miR-212-5p. Critically, we specifically isolated the renal cortex, the primary site of CsA-induced tubular injury, thereby enriching for miRNA signals from proximal tubular epithelial cells, whereas whole-kidney analysis includes glomerular, vascular, and immune compartments that may dilute cell type specific changes. Conclusions In conclusion, this study identifies the miR-212-5p/ATF6 axis as a critical regulator of CsA-induced renal fibrosis. Our findings suggest that miR-212-5p upregulation and subsequent ATF6 downregulation contribute to the activation of ER stress and the progression of renal fibrosis. Inhibition of miR-212-5p or restoration of ATF6 expression provides a promising therapeutic strategy for mitigating CsA-induced nephrotoxicity. These insights not only improve our understanding of the molecular mechanisms of CsA-induced renal fibrosis but also pave the way for novel therapeutic approaches to enhance the safety and efficacy of CsA in clinical practice. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2